Once-weekly HIV pill shines in phase 3 trials
Two Phase 3 trials (ISLEND-1, ISLEND-2) reported that people with HIV who switched from daily therapy to a once-weekly pill containing islatravir plus lenacapavir stayed virally suppressed at 48 weeks, meeting noninferiority margins. Results were presented at the International AIDS Conference and published in NEJM. Gilead and Merck are developing the regimen.
How this was made
The 30-second read
Why it matters
If the regimen maintains viral suppression through 96 weeks and clears regulatory review, it could become a first complete once-weekly oral option for virologically suppressed HIV patients, expanding the addressable market for long-acting therapies.
Market read
Phase 3 interim results show maintained viral suppression and comparable safety versus standard therapy, supporting a potential regulatory pathway for a weekly oral HIV regimen.
What to watch
The article notes a discontinuation due to hepatitis B infection in an unvaccinated participant; longer-term safety, adherence to weekly dosing, and regulatory review details remain key uncertainties.
Background
The article describes two Phase 3 trials (ISLEND-1 and ISLEND-2) testing a once-weekly oral single-tablet regimen combining islatravir and lenacapavir, where both drugs are already approved in other formulations but not together.
Ticker impact
Gilead’s lenacapavir is paired with islatravir in Phase 3 ISL/LEN results, supporting a potential once-weekly oral HIV regimen.
Shares may see a modest positive bias on trial-readout optimism, but magnitude is likely limited until regulatory/labeling milestones.
The article reports Phase 3 noninferiority and tolerability at 48 weeks, but does not include FDA approval, guidance, or financial impact figures.
Merck’s islatravir is combined with Gilead’s lenacapavir in two Phase 3 trials showing maintained viral suppression on a weekly pill.
Potential near-term sentiment lift, with follow-through dependent on full 96-week data and regulatory filing outcomes.
The newest disclosed facts are Phase 3 48-week outcomes and tolerability, but the article does not provide approval timing or revenue estimates.
Market effects
Reinforces the long-acting HIV treatment pipeline and could raise competitive expectations for oral weekly regimens versus daily therapy.
Limited direct regional impact; conference and publication are global but not tied to a specific market.
Could influence global HIV-care treatment standards and investor sentiment toward long-acting antiretroviral development.
Counterpoint
Noninferiority at 48 weeks may not translate into durable efficacy or tolerability over the full 96-week period, so the market may overreact to interim results.
Key entities
- clinical trialISLEND-1
Double-blind, active-controlled Phase 3 trial in 607 adults switching from daily Biktarvy to weekly islatravir plus lenacapavir.
- clinical trialISLEND-2
Open-label Phase 3 trial in 626 participants comparing weekly islatravir plus lenacapavir versus standard-of-care therapy.
- eventInternational AIDS Conference
Conference in Rio de Janeiro where the Phase 3 findings were presented.
- publicationThe New England Journal of Medicine
Journal where the trial results were published.
